Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Finafloxacin - MerLion Pharmaceuticals

Drug Profile

Finafloxacin - MerLion Pharmaceuticals

Alternative Names: AL-60371; BY-377; EXE 844; EXE 844b; Finafloxacin hydrochloride; Gastrochinolon; Gastroquinolone; Xtoro

Latest Information Update: 29 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Developer Alcon; MerLion Pharmaceuticals
  • Class Antibacterials; Eye disorder therapies; Fluoroquinolones; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Otitis externa
  • Phase II Helicobacter infections; Pyelonephritis; Urinary tract infections
  • No development reported Bacterial infections; Otitis media; Respiratory tract infections

Most Recent Events

  • 28 Dec 2018 No recent reports of development identified for phase-I development in Otitis-media(In children, In infants) in USA (Otic, Suspension)
  • 31 Jul 2018 MerLion regains global rights to finafloxacin after termination of licensing deal between Alcon and MerLion
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Bacterial-infections(In volunteers) in United Kingdom (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top